InMed Pharma issued 3 US patents for EB treatment, biosynthesis, ocular delivery

InMed Pharmaceuticals Inc.

Patent for INM-755 cannabinoid topical for epidermolysis bullosa granted in US, Australia, Japan, Israel.
Biosynthesis patent for manufacturing proprietary analogs granted in US, issued Sept 3, 2024.
Ocular drug delivery formulation patent granted/allowed in US, Europe, Australia, Japan, India.
Total IP portfolio now 13 patent families covering NCEs, formulations, manufacturing, methods of use.
Company continues pursuing patent protection for INM-901 (Alzheimer's) and INM-089 (dry AMD).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.